View Older Stories View More Recent Stories

Mar 24, 2016 08:00AM Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Mar 23, 2016 02:00AM Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Mar 16, 2016 02:02PM Amgen (AMGN) Comments Following Repatha Patent Win
Mar 16, 2016 12:33PM Regeneron (REGN) and Sanofi Confirm Negative Praluent Ruling, 'Strongly Disagree' with Verdict (AMGN)
Mar 16, 2016 12:30PM Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Mar 11, 2016 05:59AM Regeneron (REGN), Sanofi (SNY) Announce Sarilumab vs. Adalimumab Phase 3 Met Primary Endpoint in Active RA
Mar 11, 2016 01:00AM Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Mar 2, 2016 05:08PM Regeneron (REGN) Says NEJM Published Paper Linking ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Mar 2, 2016 05:00PM Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Feb 29, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentation
Feb 9, 2016 06:30AM Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
Feb 2, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentation
Jan 26, 2016 09:30AM Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016
Jan 25, 2016 10:30AM Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded
Jan 8, 2016 06:23AM Regeneron (REGN), Sanofi (SNY) Announce U.S. FDA Acceptance of Sarilumab BLA
Jan 8, 2016 01:00AM Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
Jan 7, 2016 09:30AM Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference
Dec 11, 2015 06:04AM UnitedHealth Will Provide Preferred Access to Praluent (REGN) (SNY)
Dec 11, 2015 01:00AM Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Dec 11, 2015 01:00AM Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Nov 24, 2015 01:00AM Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
Nov 10, 2015 06:01PM Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Nov 10, 2015 06:00PM Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Nov 8, 2015 07:08AM Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Nov 8, 2015 07:00AM Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Nov 5, 2015 09:00AM New Survey Of U.S. Adults With Diabetes Reveals Less Than Half Understand Their Risk For Vision Loss
Nov 5, 2015 08:45AM New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss
Nov 5, 2015 08:00AM Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015
Nov 4, 2015 06:30AM Regeneron Reports Third Quarter 2015 Financial and Operating Results
Oct 30, 2015 09:00AM Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Oct 23, 2015 09:30AM Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference
Oct 8, 2015 09:30AM Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015
Oct 1, 2015 04:05PM Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
Sep 28, 2015 01:00AM Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Sep 24, 2015 08:30AM Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement
Sep 21, 2015 08:00AM Regeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola
Sep 1, 2015 09:00AM Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
Aug 31, 2015 10:46AM Notable Analyst Rating Changes 8/31: (QLGC) (TWTR) (MS) Upgraded; (RGS) (UTX) (SCCO) Downgraded
Aug 4, 2015 06:30AM Regeneron Reports Second Quarter 2015 Financial and Operating Results
Jul 30, 2014 10:29AM Top 10 Trending Stocks for 07/30: Twitter (TWTR), Amgen (AMGN), Regeneron (REGN), and More...
Jul 30, 2014 09:32AM Pre-Open Stock Movers 7/30: (GFIG) (TWTR) (NQ) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Apr 16, 2014 10:38AM Notable Analyst Rating Changes 04/16: (SFUN) (TWTR) (YELP) Upgraded; (INTC) (UNH) (GDP) Downgraded
Apr 26, 2013 04:11PM Top 10 News Items for 04/22 - 04/26: Apple's Lukewarm Report; Social Media Becomes Dangerous; Q1 GDP Accelerates, Misses
View More Recent Stories View Older Stories